Having trouble accessing articles? Reset your cache.

BioNTech tackles solid tumors by pairing CAR Ts with RNA vaccines

How BioNTech aims to solve some of the biggest challenges of bringing CAR T cells to solid tumors

BioNTech is marrying two of its core technologies -- RNA therapeutics and engineered cell therapies -- to solve some of the biggest challenges of bringing CAR T cells to solid tumors.

It believes that together, the technologies will improve the in vivo expansion and persistence of the cells, keeping large enough numbers

Read the full 529 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE